Towards Healthcare
Medical Thromboelastography Machine Market Size, Trends and Shares

Medical Thromboelastography Machine Market to Hit $1020.68 Mn by 2034

The medical thromboelastography machine market is rapidly growing due to TEG’s role in major surgeries and emergency bleeding control. Recent FDA approvals of Haemonetics' TEG 6s and Werfen’s ROTEM sigma have advanced this technology for use in cardiovascular, liver, and trauma care, improving patient outcomes.

Medical Thromboelastography Machine Market Companies, Growth and Shares

The global medical thromboelastography machine market was evaluated at US$ 390 million in 2023 and is expected to attain around US$ 1020.68 million by 2034, growing at a CAGR of 9.14% from 2024 to 2034. The medical thromboelastography machine market is growing as thromboelastometry helps diagnose, manage, and monitor hemostasis and also improves certain clinical outcomes in cardiac surgery patients.

Medical Thromboelastography Machine Market Revenue 2023 - 2034

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

The medical thromboelastography machine market is growing rapidly because TEG is especially useful in major surgeries, such as heart surgery, where blood loss is a concern. It can also be used in emergencies to control bleeding after injury or hemorrhage and can be used to monitor coagulation during cardiopulmonary resuscitation, anticoagulation management in patients with total heart failure, extracorporeal membrane oxygenation, and predictive bleeding during invasive procedures in patients with cirrhosis and coagulopathy, to identify susceptible patients after central venous cannulation in patients with cirrhosis and to patients who can undergo minor surgery without the risk of bleeding despite strong PT.

Thromboelastography (TEG) is a diagnostic test with many advantages over other tests. As evidence of its therapeutic efficacy increases, TEG has become a more widely used test. TEG can detect coagulation disorders in patients with intracranial hemorrhage and hematoma expansion. TEG can also be used in the treatment of liver disease, blood loss, severe liver disease, hypertension, and hemorrhagic disease.

The Impact of Rapid TEG Assays: To Support the Market’s Expansion

The development of the rapid diagnostic test (r-TEG) ​​represents a significant advance in diagnosis and improves hemostatic control in the clinic. R-TEG uses tissues to replace the traditional kaolin-cephalin reagent to activate blood coagulation and speed up the diagnostic process by participating in the extrinsic coagulation process.

This innovation, which can be tested in 15 minutes, is particularly useful in monitoring blood pressure in trauma patients. In addition, the application of thromboelastometry in cardiac surgery is improving the detection, management, and monitoring of hemostatic conditions, thereby increasing the demand for the medical thromboelastography machine market. The development of diagnostic tools should contribute to economic growth by improving patient outcomes and hospital operations.

  • In April 2024, Haemonetics Corporation, a global healthcare company focused on delivering innovative therapies to improve patient outcomes, announced that its TEG 6s Hemostasis Analysis System has received a 510(k) withdrawal from the U.S. Food and Drug Administration (FDA) Hemostasis-HN test kit. This new box expands the viscoelastic testing capabilities of Haemonetics’ TEG 6 for fully heparinized patients in adult cardiovascular/surgical and liver transplantation in both laboratory and point-of-care settings.
  • In July 2022, Werfen’s ROTEM sigma Thromboelastometry System, which enables rapid assessment of critical bleeding at the point of care to reduce inappropriate transfusions and enhanced outcomes, received 510(k) clearance from the U.S. Food and Drug Administration.
  • VEM is best studied in surgery and trauma and shows significant promise for use in the emergency department. It has advantages over traditional coagulation tests; it provides information about the entire coagulation cascade and can generally be monitored more rapidly than standard coagulation performed in point-of-care.
  • In January 2022, the use of thromboelastography (TEG) in pediatric trauma patients has not been extensively studied. Mortality is higher in patients with TEG-induced coagulopathy. All TEG values ​​were associated with increased mortality when they reached transfusion-trigger cut points.

Requirement of Efficiency and Precision: Significant Opportunity for the Market

The integration of automation and AI into thromboelastography testing offers a significant opportunity to increase the efficiency and accuracy of these diseases. It provides an additional, specific assessment of the severity and various coagulation disorders. TEG technology can be used in many clinical areas, focusing on the point of care, and providing immediate analysis of bone formation and fracture. The development of algorithms that incorporate TEG analysis to manage bleeding patients has been shown to have the potential to reduce blood transfusions and improve clinical outcomes, and the medical thromboelastography machine market for substantial growth as healthcare providers adopt these advanced solutions.

Slower Diagnostics and Highers Costs to Create Challenge

The growth of the medical thromboelastography machine market is limited by several important factors. The diagnostic process is not as fast as the empirical method, and valuable time can be consumed in critical situations. Furthermore, the overall cost of thromboelastometry can be higher than traditional coagulation tests when accounting for recalibration and maintenance expenses. It is limited to small areas in the region, further restricting access. Furthermore, routine administration of tranexamic acid, which is cost-effective and safe, often requires assessment of fibrinolysis, and special training is required for the quality of its use and interpretation of results. Also, the technology is inadequate in addressing hypothermia-related coagulopathies, further limiting its medical thromboelastography machine market applicability and growth.

Regional Insights

Well Established Healthcare Sector: North America to Sustain as a Leader

By region North America is dominated in the medical thromboelastography machine market as it is the largest medical market in the world and accounts for more than 40% of the global medical patient technology industry. Medical technology innovators work to provide doctors and other healthcare professionals with the best tools to diagnose and treat patients. This commitment drives more than 6,500 medical technology companies, mostly small and medium-sized enterprises, that produce medical technology every day in the United States.

The medical technology industry is a manufacturing success and one of the fastest-growing industries in the United States, that merges rapid innovation with precision product building and distribution. The industry is a world leader, with homegrown R&D, domestic manufacturing in communities large and small, and worldwide exports of American-made products. The advancements in medical technology throughout North America due to the continuous development that has led to the growth of the medical thromboelastography machine market.

Asia Pacific is expected to witness significant growth in the medical thromboelastography machine market during the forecast period as healthcare providers in the region adopt more advanced technologies, including artificial intelligence and cloud technology in their care models. Increasing healthcare spending in the Asia Pacific region is inevitable. Fast-aging populations, growing middle classes, increasing health awareness, and favorable government initiatives are few factors that promote the growth of the market in Asian area.

Segmental Insights

By Type

By type, single-channel and double-channel segments constitute the medical thromboelastometry machine market as it reduces the risk of sampling and measurement errors. Each chamber has a platform with a disposable cup where the blood sample is collected and a detection pin suspended in its center. The four-channel segment is the fastest growing and it allows experiments with different activators, platelet blockade, and aprotinin or heparinase in addition to four channels at the simultaneous testing time.

By Application

In terms of application, the hospital segment dominates the medical thromboelastography machine market as it is used to evaluate the hemostatic properties of blood, identify coagulopathies, and guide the management of blood products. Whereas the clinic's segment is fastest growing as the need for organ transplantation and blood loss in heart surgeries, heart transplants, and major trauma.

Recent Developments

  • In May 2023, QuidelOrtho and Render organized a New Product Development Conference for IHTEG6 thromboelastography, the newest member of the IHTEG series, at the 20th China Association of Clinical Laboratory Applications (CACLP).
  • In March 2024, Haemonetics Corporation Julie Bergeman announced the TEG® 6s hemostasis system uses thromboelastography to provide continuous measurement of clot elasticity.

Medical Thromboelastography Machine Market Companies

Top Companies in the Medical Thromboelastography Machine Market

  • Aemonetics Corporation
  • Instrumentation Laboratory
  • Framar Hemologix Srl, Medirox AB
  • Diagnostica Stago
  • Life Diagnostics
  • SHINHUA
  • Haemonetics, Lepu Technology
  • Biomart, Medcaptain,
  • Ud-bio Chongqing Nanfang
  • WITEYE
  • Render
  • Guizhou Jinjiu Biotech
  • Chongqing Dingrun
  • Zhejiang Shengyu
  • Bio-zircon
  • WerfenLife
  • Sienco

Segments Covered in the Market

By Type

  • Single and Double Channel
  • Four Channels
  • Others

By Application

  • Hospitals
  • Clinics
  • Blood Banks
  • Academic Institutes

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America
  • Insight Code: 5312
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.

FAQ's

The global medical thromboelastography machine market is expected to grow at a CAGR of 9.14% from 2024 to 2034, driven by increased demand for efficient diagnostic tools in cardiac surgeries, trauma care, and emergency departments.

Despite its benefits, the market faces challenges such as higher costs associated with thromboelastography testing, slower diagnostic processes compared to empirical methods, and a limited range of effectiveness for certain coagulopathies. Additionally, these devices require specific training for accurate use, which may impact market adoption.

Asia Pacific is anticipated to see significant growth in the medical thromboelastography machine market during the forecast period, driven by rising healthcare investments, aging populations, and an increasing adoption of advanced medical technologies such as AI in patient care models.